Single-time-point [68Ga]Ga-DOTATATE-PET/CT for model-based prediction of the time-integrated activity of [177Lu]Lu-DOTATATE during therapy

被引：0
|
作者：
Vasic, V. [1 ,2 ]
Gustafsson, J. [3 ]
Yousefzadeh-Nowshahr, E. [1 ,2 ]
Beer, A. [1 ]
Gleisner, K. Sjoegreen [3 ]
Glatting, G. [1 ,2 ]
机构：
[1] Ulm Univ, Med Ctr, Dept Nucl Med, Ulm, Germany
[2] Univ Ulm, Med Radiat Phys, Dept Nucl Med, Ulm, Germany
[3] Lund Univ, Med Radiat Phys, Lund, Sweden
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2023年 / 50卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP-904
引用
收藏
页码：S403 / S403
页数：1
相关论文
共 50 条
  • [31] Time-integrated activity coefficients calculated using a physiologically based pharmacokinetic model and sampling schedules for [177Lu]Lu-PSMA-617 radioligand therapy
    Orlov, C.
    Vasic, V.
    Beer, A. J.
    Glatting, G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S634 - S635
  • [32] Baseline [68Ga]Ga-PSMA-11 PET/CT before [177Lu]Lu-PSMA-617 Radioligand Therapy: Value of PSMA-Uptake Thresholds in Predicting Targetable Lesions
    Groener, Daniel
    Schneider, Sina
    Baumgarten, Justus
    Happel, Christian
    Klimek, Konrad
    Mader, Nicolai
    Ngoc, Christina Nguyen
    Wichert, Jennifer
    Mandel, Philipp
    Tselis, Nikolaos
    Gruenwald, Frank
    Sabet, Amir
    CANCERS, 2023, 15 (02)
  • [33] Single-time-point dosimetry for tumour lesions during [177Lu]Lu-PSMA-617 therapy using non-linear mixedeffects modeling
    Hardiansyah, D.
    Yousefzadeh-Nowshahr, E.
    Kind, F.
    Beer, A. J.
    Ruf, J.
    Mix, M.
    Glatting, G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S71 - S72
  • [34] Diagnosis of Men-I Syndrome on Ga-68-DOTANOC PET-CT and Role of Peptide Receptor Radionuclide Therapy With Lu-177-DOTATATE
    Gupta, Santosh Kumar
    Singla, Suhas
    Damle, Nishikant A.
    Agarwal, Krishankant
    Bal, Chandersekhar
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2012, 10 (04)
  • [35] Single-Time-Point Renal Dosimetry Using Nonlinear Mixed-Effects Modeling and Population-Based Model Selection in [177Lu]Lu-PSMA-617 Therapy
    Hardiansyah, Deni
    Yousefzadeh-Nowshahr, Elham
    Kind, Felix
    Beer, Ambros J.
    Ruf, Juri
    Glatting, Gerhard
    Mix, Michael
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65 (04) : 566 - 572
  • [36] Prediction of transient bone marrow suppression after [177Lu]Lu-DOTA-TATE treatment using [68Ga]Ga-DOTA-TOC PET/CT and clinical parameters in patients with gastroenteropancreatic neuroendocrine tumors
    Ryoo, H.
    Choi, H.
    Paeng, J.
    Kang, K.
    Cheon, G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (SUPPL 1) : S140 - S141
  • [37] Early molecular imaging response assessment based on determination of total viable tumor burden in [68Ga]Ga-PSMA-11 PET/CT independently predicts overall survival in [177Lu]Lu-PSMA-617 radioligand therapy
    Rosar, Florian
    Wenner, Felix
    Khreish, Fadi
    Dewes, Sebastian
    Wagenpfeil, Gudrun
    Hoffmann, Manuela A.
    Schreckenberger, Mathias
    Bartholoma, Mark
    Ezziddin, Samer
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (05) : 1584 - 1594
  • [38] Combined [18F]FDG and [68Ga]Ga-PSMA-11 PET/CT for [177Lu]-PSMA-Radioligand therapy assessment with long-axial field of view (LAFOV) PET/CT
    Alberts, I.
    Schepers, R.
    Zeimpekis, K.
    Viscione, M.
    Rominger, A.
    Afshar-Oromieh, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S268 - S268
  • [39] Early molecular imaging response assessment based on determination of total viable tumor burden in [68Ga]Ga-PSMA-11 PET/CT independently predicts overall survival in [177Lu]Lu-PSMA-617 radioligand therapy
    Florian Rosar
    Felix Wenner
    Fadi Khreish
    Sebastian Dewes
    Gudrun Wagenpfeil
    Manuela A. Hoffmann
    Mathias Schreckenberger
    Mark Bartholomä
    Samer Ezziddin
    European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49 : 1584 - 1594
  • [40] First outcomes from OZM-067-a multicenter single arm study of 177Lu-DOTATATE therapy for primary site agnostic 68Ga-DOTATATE PET positive progressive metastatic neuroendocrine tumors
    Wong, Rebecca
    Laidley, David
    Myrehaug, Sten
    Juergens, Rosalyn
    Metser, Ur
    Ezzat, Shereen
    Yeung, Ivan
    Driscoll, Brandon
    Gabrys, Judy
    Publicover, Julia
    Shessel, Andrea
    Levine, Oren
    Veit-Haibach, Patrick
    Mohan, Ravi
    Breen, Stephen
    Zukotynski, Katherine
    Mesci, Aruz
    Brierley, James
    Lajkosz, Katherine
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
12345